5 results
Objectives: The following trial objectives for adolescent patients (from 12 and up to 18 years of age) with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS) are to:Primary:* Assess the effect of eculizumab on TMA-Event Free status…
Objectives: The following trial objectives for adult patients with plasma therapy-resistantAtypical Hemolytic-Uremic Syndrome (aHUS) are to:Primary:• Assess the effect of eculizumab to reduce thrombotic microangiopathy (TMA) asindicated by…
Objectives: The following trial objectives for adult patients with plasma therapy-resistantAtypical Hemolytic-Uremic Syndrome (aHUS) are to:Primary:• Assess the effect of eculizumab to reduce thrombotic microangiopathy (TMA) asindicated by…
The OneShotTM System procedure is designed to provide the anatomical and physiologic benefits of catheter-based RDN at lesser risk to the subject, due to a reduction of complexity of the procedure and design improvements intended to enhance…
To assess the effects and costs of the use of the Australian Medical Sheepskin and usual care with regard to the prevention of sacral pressure ulcers in somatic nursing home clients, versus usual care only.